A 17-molecule set as a predictor of complete response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer.

Recently, neoadjuvant chemotherapy with docetaxel/cisplatin/5-fluorouracil (NAC-DCF) was identified as a novel strong regimen with a high rate of pathological complete response (pCR) in advanced esophageal cancer in Japan. Predicting pCR will contribute to the therapeutic strategy and the prevention...

Full description

Bibliographic Details
Main Authors: Hajime Fujishima, Shoichi Fumoto, Tomotaka Shibata, Kohei Nishiki, Yoshiyuki Tsukamoto, Tsuyoshi Etoh, Masatsugu Moriyama, Norio Shiraishi, Masafumi Inomata
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5685591?pdf=render
id doaj-f72b8268302c407f9c773c0fce894a8c
record_format Article
spelling doaj-f72b8268302c407f9c773c0fce894a8c2020-11-25T01:30:48ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-011211e018809810.1371/journal.pone.0188098A 17-molecule set as a predictor of complete response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer.Hajime FujishimaShoichi FumotoTomotaka ShibataKohei NishikiYoshiyuki TsukamotoTsuyoshi EtohMasatsugu MoriyamaNorio ShiraishiMasafumi InomataRecently, neoadjuvant chemotherapy with docetaxel/cisplatin/5-fluorouracil (NAC-DCF) was identified as a novel strong regimen with a high rate of pathological complete response (pCR) in advanced esophageal cancer in Japan. Predicting pCR will contribute to the therapeutic strategy and the prevention of surgical invasion. However, a predictor of pCR after NAC-DCF has not yet been developed. The aim of this study was to identify a novel predictor of pCR in locally advanced esophageal cancer treated with NAC-DCF.A total of 32 patients who received NAC-DCF followed by esophagectomy between June 2013 and March 2016 were enrolled in this study. We divided the patients into the following 2 groups: pCR group (9 cases) and non-pCR group (23 cases), and compared gene expressions between these groups using DNA microarray data and KeyMolnet. Subsequently, a validation study of candidate molecular expression was performed in 7 additional cases.Seventeen molecules, including transcription factor E2F, T-cell-specific transcription factor, Src (known as "proto-oncogene tyrosine-protein kinase of sarcoma"), interferon regulatory factor 1, thymidylate synthase, cyclin B, cyclin-dependent kinase (CDK) 4, CDK, caspase-1, vitamin D receptor, histone deacetylase, MAPK/ERK kinase, bcl-2-associated X protein, runt-related transcription factor 1, PR domain zinc finger protein 1, platelet-derived growth factor receptor, and interleukin 1, were identified as candidate molecules. The molecules were mainly associated with pathways, such as transcriptional regulation by SMAD, RB/E2F, and STAT. The validation study indicated that 12 of the 17 molecules (71%) matched the trends of molecular expression.A 17-molecule set that predicts pCR after NAC-DCF for locally advanced esophageal cancer was identified.http://europepmc.org/articles/PMC5685591?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Hajime Fujishima
Shoichi Fumoto
Tomotaka Shibata
Kohei Nishiki
Yoshiyuki Tsukamoto
Tsuyoshi Etoh
Masatsugu Moriyama
Norio Shiraishi
Masafumi Inomata
spellingShingle Hajime Fujishima
Shoichi Fumoto
Tomotaka Shibata
Kohei Nishiki
Yoshiyuki Tsukamoto
Tsuyoshi Etoh
Masatsugu Moriyama
Norio Shiraishi
Masafumi Inomata
A 17-molecule set as a predictor of complete response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer.
PLoS ONE
author_facet Hajime Fujishima
Shoichi Fumoto
Tomotaka Shibata
Kohei Nishiki
Yoshiyuki Tsukamoto
Tsuyoshi Etoh
Masatsugu Moriyama
Norio Shiraishi
Masafumi Inomata
author_sort Hajime Fujishima
title A 17-molecule set as a predictor of complete response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer.
title_short A 17-molecule set as a predictor of complete response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer.
title_full A 17-molecule set as a predictor of complete response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer.
title_fullStr A 17-molecule set as a predictor of complete response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer.
title_full_unstemmed A 17-molecule set as a predictor of complete response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer.
title_sort 17-molecule set as a predictor of complete response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2017-01-01
description Recently, neoadjuvant chemotherapy with docetaxel/cisplatin/5-fluorouracil (NAC-DCF) was identified as a novel strong regimen with a high rate of pathological complete response (pCR) in advanced esophageal cancer in Japan. Predicting pCR will contribute to the therapeutic strategy and the prevention of surgical invasion. However, a predictor of pCR after NAC-DCF has not yet been developed. The aim of this study was to identify a novel predictor of pCR in locally advanced esophageal cancer treated with NAC-DCF.A total of 32 patients who received NAC-DCF followed by esophagectomy between June 2013 and March 2016 were enrolled in this study. We divided the patients into the following 2 groups: pCR group (9 cases) and non-pCR group (23 cases), and compared gene expressions between these groups using DNA microarray data and KeyMolnet. Subsequently, a validation study of candidate molecular expression was performed in 7 additional cases.Seventeen molecules, including transcription factor E2F, T-cell-specific transcription factor, Src (known as "proto-oncogene tyrosine-protein kinase of sarcoma"), interferon regulatory factor 1, thymidylate synthase, cyclin B, cyclin-dependent kinase (CDK) 4, CDK, caspase-1, vitamin D receptor, histone deacetylase, MAPK/ERK kinase, bcl-2-associated X protein, runt-related transcription factor 1, PR domain zinc finger protein 1, platelet-derived growth factor receptor, and interleukin 1, were identified as candidate molecules. The molecules were mainly associated with pathways, such as transcriptional regulation by SMAD, RB/E2F, and STAT. The validation study indicated that 12 of the 17 molecules (71%) matched the trends of molecular expression.A 17-molecule set that predicts pCR after NAC-DCF for locally advanced esophageal cancer was identified.
url http://europepmc.org/articles/PMC5685591?pdf=render
work_keys_str_mv AT hajimefujishima a17moleculesetasapredictorofcompleteresponsetoneoadjuvantchemotherapywithdocetaxelcisplatinand5fluorouracilinesophagealcancer
AT shoichifumoto a17moleculesetasapredictorofcompleteresponsetoneoadjuvantchemotherapywithdocetaxelcisplatinand5fluorouracilinesophagealcancer
AT tomotakashibata a17moleculesetasapredictorofcompleteresponsetoneoadjuvantchemotherapywithdocetaxelcisplatinand5fluorouracilinesophagealcancer
AT koheinishiki a17moleculesetasapredictorofcompleteresponsetoneoadjuvantchemotherapywithdocetaxelcisplatinand5fluorouracilinesophagealcancer
AT yoshiyukitsukamoto a17moleculesetasapredictorofcompleteresponsetoneoadjuvantchemotherapywithdocetaxelcisplatinand5fluorouracilinesophagealcancer
AT tsuyoshietoh a17moleculesetasapredictorofcompleteresponsetoneoadjuvantchemotherapywithdocetaxelcisplatinand5fluorouracilinesophagealcancer
AT masatsugumoriyama a17moleculesetasapredictorofcompleteresponsetoneoadjuvantchemotherapywithdocetaxelcisplatinand5fluorouracilinesophagealcancer
AT norioshiraishi a17moleculesetasapredictorofcompleteresponsetoneoadjuvantchemotherapywithdocetaxelcisplatinand5fluorouracilinesophagealcancer
AT masafumiinomata a17moleculesetasapredictorofcompleteresponsetoneoadjuvantchemotherapywithdocetaxelcisplatinand5fluorouracilinesophagealcancer
AT hajimefujishima 17moleculesetasapredictorofcompleteresponsetoneoadjuvantchemotherapywithdocetaxelcisplatinand5fluorouracilinesophagealcancer
AT shoichifumoto 17moleculesetasapredictorofcompleteresponsetoneoadjuvantchemotherapywithdocetaxelcisplatinand5fluorouracilinesophagealcancer
AT tomotakashibata 17moleculesetasapredictorofcompleteresponsetoneoadjuvantchemotherapywithdocetaxelcisplatinand5fluorouracilinesophagealcancer
AT koheinishiki 17moleculesetasapredictorofcompleteresponsetoneoadjuvantchemotherapywithdocetaxelcisplatinand5fluorouracilinesophagealcancer
AT yoshiyukitsukamoto 17moleculesetasapredictorofcompleteresponsetoneoadjuvantchemotherapywithdocetaxelcisplatinand5fluorouracilinesophagealcancer
AT tsuyoshietoh 17moleculesetasapredictorofcompleteresponsetoneoadjuvantchemotherapywithdocetaxelcisplatinand5fluorouracilinesophagealcancer
AT masatsugumoriyama 17moleculesetasapredictorofcompleteresponsetoneoadjuvantchemotherapywithdocetaxelcisplatinand5fluorouracilinesophagealcancer
AT norioshiraishi 17moleculesetasapredictorofcompleteresponsetoneoadjuvantchemotherapywithdocetaxelcisplatinand5fluorouracilinesophagealcancer
AT masafumiinomata 17moleculesetasapredictorofcompleteresponsetoneoadjuvantchemotherapywithdocetaxelcisplatinand5fluorouracilinesophagealcancer
_version_ 1725089803356078080